Milestone Scientific heads into its Q1 2026 earnings aftermath with two sharply diverging signals: shorts have retreated at remarkable speed, while options traders just flashed the most defensive reading on record.
The short interest story has been dramatic. Estimated short interest peaked near 5.5 million shares in mid-April, a roughly 100x surge from the roughly 45,000-share baseline seen in early April. Since then, the unwind has been equally sharp — shorts fell 59% in a single week to just 1.2% of the float, with daily reductions recorded in every session from May 4 through May 12. The lending market reflects the same retreat: cost to borrow eased to 1.83% from a brief spike above 5% in late April. Availability has also loosened considerably, with utilisation now at 42%, well down from the 97% peak hit on April 17. The borrow market is no longer stressed.
Options positioning tells a different story. The put/call ratio jumped to 0.0435 on May 12 — more than four standard deviations above its 20-day mean of 0.009 and the highest reading in the past year. That is a sharp one-day move and stands in direct contrast to the short interest unwind. While shorts were covering, options traders appear to have added downside protection just ahead of earnings. The signal is notable precisely because MLSS options activity is ordinarily skewed heavily toward calls.
Those cautions proved warranted. Q1 EPS came in at -$0.01, matching estimates, but revenue of $2.16M missed the $2.25M consensus. The stock had already dropped 12.5% on May 12 before results hit after the close, extending its one-month decline to roughly flat on a net basis despite the 27% run-up through late April. The only piece of operational news that could act as a counterweight was the May 7 announcement of an expanded CompuFlo® Medical advisor programme and growing national clinical adoption — a modest positive that preceded the earnings miss.
The sole covering analyst, Benchmark's Bruce Jackson, carried a Speculative Buy rating with a $1.00 price target as of November 2025 — that data is more than 170 days old and should be treated as background colour rather than current guidance. The stock at $0.35 sits at a 65% discount to that target, but with no fresh Street activity on record, the gap reflects stale coverage rather than a meaningful divergence.
The setup now is straightforward to describe. Shorts have largely gone — the 59% weekly collapse in estimated short interest removes any obvious squeeze dynamic. The options market moved defensively right before an earnings miss. What matters next is whether the Q1 revenue shortfall is an isolated data point or the beginning of a deceleration narrative that re-attracts bearish positioning as the company's advisor expansion story gets tested against actual sales growth.
See the live data behind this article on ORTEX.
Open MLSS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
